文獻名:P22 Viral Capsids as Nanocomposite High-Relaxivity MRI Contrast Agents
作者:Shefah Qazi †‡, Lars O. Liepold †‡, Md Joynal Abedin †‡, Ben Johnson †‡, Peter Prevelige ,Joseph A. Frank #, and Trevor Douglas *†‡
†Chemistry and Biochemistry Department and ‡Center for Bio-Inspired Nanomaterials, Montana State University, Bozeman, Montana, 59717, United States
Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 35294, United States
Frank Laboratory, Radiology and Imaging Sciences, Clinical Center, and #National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland 20892, United States
摘要:Attachment of multiple chelated Gd3+ ions to the interior of bacteriophage P22 viral capsids affords nanoscale MRI contrast agents with extremely high relaxivity values. Highly fenestrated “wiffleball” morphology is unique to P22 and assures water exchange between the environment and interior cavity of the capsid. The cavity of P22 “wiffleball” was functionalized with a branched oligomer comprising multiple DTPA–Gd complexes resulting in an impressive payload of 1,900 Gd3+ ions inside each 64 nm capsid. High relaxivities of r1,ionic= 21.7 mM–1 s–1 and r1,particle = 41,300 mM–1 s–1 at 298 K, 0.65 T (28 MHz) are reported, withr1/r2 ratio of 0.80 and optimized rotational correlation time for this system. Specific design modifications are suggested for future improvements of viral capsid-based MRI contrast agents directed toward clinical translation.
關鍵詞:viral capsid, VLP, bacteriophage P22, magnetic resonance imaging, MRI, imaging agent, contrast agent, T1, relaxivity, gadolinium, DTPA-Gd, azide-alkyne click chemistry, nanoparticle, nanocomposite, protein cages, payload
免責聲明
- 凡本網注明“來源:化工儀器網”的所有作品,均為浙江興旺寶明通網絡有限公司-化工儀器網合法擁有版權或有權使用的作品,未經本網授權不得轉載、摘編或利用其它方式使用上述作品。已經本網授權使用作品的,應在授權范圍內使用,并注明“來源:化工儀器網”。違反上述聲明者,本網將追究其相關法律責任。
- 本網轉載并注明自其他來源(非化工儀器網)的作品,目的在于傳遞更多信息,并不代表本網贊同其觀點和對其真實性負責,不承擔此類作品侵權行為的直接責任及連帶責任。其他媒體、網站或個人從本網轉載時,必須保留本網注明的作品第一來源,并自負版權等法律責任。
- 如涉及作品內容、版權等問題,請在作品發表之日起一周內與本網聯系,否則視為放棄相關權利。